Rylaze

Rylaze

 Rylaze

Asparaginase Erwinia Chrysanthemi (recombinant)¬-rywn

Injection: 10 mg/0.5 mL Solution in a Single-dose Vial

Jazz Pharmaceuticals

Medical Use

Rylaze is an enzyme specifically targeting asparagine, used as part of a multi-agent chemotherapy regimen to treat acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in both adults and children aged one month or older who are allergic to E. coli-derived asparaginase.

Recommended Dosage: When substituting a long-acting asparaginase product, the recommended dose is 25 mg/m², administered intramuscularly every 48 hours.